Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
March 8, 2017
- MHLW’s Guide to Recommend Against Prescribing Antibacterials for Colds, Diarrhea
March 8, 2017
- Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW to Update Its Generic Roadmap in Line with Govt Target: Official
March 7, 2017
- PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
March 6, 2017
- Official Raw Plasma Prices for FY2017 Virtually Flat: MHLW Panel
March 6, 2017
- Panel OKs Orphan Designations for Olaparib, Inotuzumab Ozogamicin
March 6, 2017
- Opdivo Approval for Head and Neck Cancer Expected in Late March-Early April
March 6, 2017
- MHLW Advisory Committee OKs Ninlaro, Sovaldi for Genotypes 3-6
March 6, 2017
- MHLW OKs Add’l Indications for Revlimid, Other Drugs
March 3, 2017
- Orphan Status Dropped for 3 Drugs, Designation Given to Canakinumab
March 3, 2017
- Industry Reps Call for Early Discussions on Inclusion of Vaccines in Public Vaccination Programs: Hearings
March 3, 2017
- MHLW Advisory Panel Backs Shionogi’s Pediatric ADHD Drug
March 3, 2017
- New CEFP Working Group on Assessment and Analysis Launches Discussions
March 2, 2017
- Non-Partisan Lawmaker Group on Healthcare Boots Up, Plans Fortnightly Hearings
March 2, 2017
- MHLW to Tap NCCHD Database to Improve Pediatric Drug Use Environment
March 2, 2017
- Conduct Surprise Inspections on Wholesalers/Pharmacies by March-End, MHLW Asks Pref. Authorities
March 2, 2017
- MHLW OKs 53 NMEs in 2016
March 2, 2017
- 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…